Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Accumulated Expenses (2017 - 2025)

Adma Biologics (ADMA) has disclosed Accumulated Expenses for 14 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 1.92% year-over-year to $6.0 million, compared with a TTM value of $6.0 million through Dec 2025, up 1.92%, and an annual FY2025 reading of $6.0 million, up 1.92% over the prior year.
  • Accumulated Expenses was $6.0 million for Q4 2025 at Adma Biologics, up from $105000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $33.7 million in Q1 2024 and bottomed at $105000.0 in Q3 2025.
  • Average Accumulated Expenses over 5 years is $9.7 million, with a median of $4.1 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses skyrocketed 2718.44% in 2023, then tumbled 99.62% in 2025.
  • Year by year, Accumulated Expenses stood at $4.1 million in 2021, then rose by 0.49% to $4.1 million in 2022, then surged by 705.65% to $32.9 million in 2023, then crashed by 82.1% to $5.9 million in 2024, then increased by 1.92% to $6.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for ADMA at $6.0 million in Q4 2025, $105000.0 in Q3 2025, and $3.1 million in Q2 2025.